The contribution of S100B to the glioprotective effects of valproic and arundic acids

Document Type : Original Article


Shiraz Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran


Objective(s): Valproic and arundic acids are astrocytes-modulating agents with potential effects in the treatment of Alzheimer’s disease (AD). S100B is an astrocytic cytokine with a possible role in the pathogenesis of AD. In this study, we aimed to assess the glioprotective effects of valproic and arundic acids against amyloid-β-peptide (Aβ)-induced glial death and contribution of S100B to the glioprotective effects of these agents in an astrocytic culture.   
Materials and Methods: We used Aβ25–35 at a concentration of 200 μM in 1321N1 astrocyte cells. We treated the cells with valproic acid (0.5 and 1 mM) and/or arundic acid 50 µM for 24 hr. Methylthiazolyldiphenyl-tetrazolium bromide (MTT) test was used to measure cell viability. The intracellular and extracellular S100B levels were measured using an ELISA kit. The data were analyzed using one-way analysis of variance followed by the Tukey’s test.   
Results: Aβ (200 µM) decreased the cell viability compared to the control group (P<0.001). Valproic acid (0.5 and 1 mM) and arundic acid (50 µM) ameliorated the gliotoxic effects of Aβ (P<0.05). The Aβ-treated group had higher S100B levels (both intracellular and extracellular) compared to the negative control groups (P<0.001). Arundic and valproic acids (0.5 and 1 mM) decreased both the intracellular and extracellular S100B levels compared to the Aβ-treated group (P<0.001).
Conclusion: By considering homeostatic and neuroprotective functions of astrocyte, the astroprotective effects and the attenuation of S100B level may be responsible, at least in part, for the beneficial effects of valproic and arundic acids in AD.


Main Subjects

1. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012; 148:1204-1222.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297:353-356.
3. Verkhratsky A, Zorec R, Rodríguez JJ, Parpura V. Astroglia dynamics in ageing and Alzheimer’s disease. Curr Opin Pharmacol 2016; 26:74-79.
4. Akiyama H, Schwab C, Kondo H, Mori H, Kametani F, Ikeda K, et al. Granules in glial cells of patients with Alzheimer’s disease are immunopositive for C-terminal sequences of β-amyloid protein. Neurosci Lett 1996; 206:169-172.
5. Nielsen HM, Mulder SD, Beliën JA, Musters RJ, Eikelenboom P, Veerhuis R. Astrocytic Aβ1‐42 uptake is determined by Aβ‐aggregation state and the presence of amyloid‐associated proteins. Glia 2010; 58:1235-1246.
6. Liu B, Teschemacher AG, Kasparov S. Astroglia as a cellular target for neuroprotection and treatment of neuro‐psychiatric disorders. Glia 2017; 65:1098-1136.
7. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat Med 2004; 10:719-726.
8. Nagele RG, D’Andrea MR, Lee H, Venkataraman V, Wang H-Y. Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 2003; 971:197-209.
9. Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 1997; 56:901-911.
10. Masliah E, Hansen L, Alford M, Deteresa R, Mallory M. Deficient glutamate tranport is associated with neurodegeneration in Alzheimer’s disease. Ann Neurol 1996; 40:759-766.
11. Fuller S, Steele M, Münch G. Activated astroglia during chronic inflammation in Alzheimer’s disease—do they neglect their neurosupportive roles? Mutat Res 2010; 690:40-49.
12. Newman SF, Sultana R, Perluigi M, Coccia R, Cai J, Pierce WM, et al. An increase in S-glutathionylated proteins in the Alzheimer’s disease inferior parietal lobule, a proteomics approach. J Neurosci Res 2007; 85:1506-1514.
13. Rodriguez J, Olabarria M, Chvatal A, Verkhratsky A. Astroglia in dementia and Alzheimer’s disease. Cell Death Differ 2009; 16:378-385.
14. Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 2014; 81:229-248.
15. Thal DR. The role of astrocytes in amyloid β-protein toxicity and clearance. Exp Neurol 2012; 236:1-5.
16. Landmark CJ. Antiepileptic Drugs in Non-Epilepsy Disorders. CNS Drugs 2008; 22:27-47.
17. Chen PS, Peng G, Li G, Yang S, Wu X, Wang C, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006; 11:1116-1125.
18. Asano T, Mori T, Shimoda T, Shinagawa R, Satoh S, Yada N, et al. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr Drug Targets CNS Neurol Disord 2005; 4:127-142.
19. Mori T, Town T, Tan J, Tateishi N, Asano T. Modulation of astrocytic activation by arundic acid (ONO-2506) mitigates detrimental effects of the apolipoprotein E4 isoform after permanent focal ischemia in apolipoprotein E knock-in mice. J Cereb Blood Flow Metab 2005; 25:748-762.
20. Saha P, Biswas SC. Amyloid-β induced astrocytosis and astrocyte death: Implication of FoxO3a–Bim–caspase3 death signaling. Mol Cell Neurosci 2015; 68:203-211.
21. Feng Z, Zhang J-t. Protective effect of melatonin on β-amyloid-induced apoptosis in rat astroglioma c6 cells and its mechanism. Free Radic Biol Med 2004; 37:1790-1801.
22. Kobayashi K, Hayashi M, Nakano H, Shimazaki M, Sugimori K, Koshino Y. Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer’s disease. J Alzheimers Dis 2004; 6:623-632.
23. Smale G, Nichols NR, Brady DR, Finch CE, Horton Jr WE. Evidence for apoptotic cell death in Alzheimer’s disease. Exp Neurol 1995; 133:225-230.
24. Verkhratsky A, Parpura V. Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders. Neurobiol Dis 2016; 85:254-261.
25. Rajkowska G, A Stockmeier C. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 2013; 14:1225-1236.
26. Rodríguez JJ, Verkhratsky A. Neuroglial roots of neurodegenerative diseases? Mol Neurobiol 2011; 43:87-96.
27. Beauquis J, Pavía P, Pomilio C, Vinuesa A, Podlutskaya N, Galvan V, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer’s disease. Exp Neurol 2013; 239:28-37.
28. Kulijewicz-Nawrot M, Verkhratsky A, Chvatal A, Sykova E, Rodríguez JJ. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer’s disease. J Anat 2012; 221:252-262.
29. Yeh C-Y, Vadhwana B, Verkhratsky A, Rodríguez JJ. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer’s disease. ASN Neuro 2011; 3:271-279.
30. Mori T, Town T, Tan J, Yada N, Horikoshi Y, Yamamoto J, et al. Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J Pharmacol Exp Ther 2006; 318:571-578.
31. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21:383-421.
32. Griffin W, Sheng J, Royston M, Gentleman S, McKenzie J, Graham D, et al. Glial-neuronal interactions in Alzheimer’s disease: The potential role of a ‘cytokine cycle’in disease progression. Brain Pathol 1998; 8:65-72.
33. Mrak RE, Griffinb WST. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease. Neurobiol Aging 2001; 22:915-922.
34. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 2010; 35:870-880.
35. Nalivaeva NN, Belyaev ND, Lewis DI, Pickles AR, Makova NZ, Bagrova DI, et al. Effect of sodium valproate administration on brain neprilysin expression and memory in rats. J Mol Neurosci 2012; 46:569-577.
36. Lai JS, Zhao C, Warsh JJ, Li PP. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol 2006; 539:18-26.
37. Yao Z-G, Liang L, Liu Y, Zhang L, Zhu H, Huang L, et al. Valproate improves memory deficits in an Alzheimer’s disease mouse model: investigation of possible mechanisms of action. Cell Mol Neurobiol 2014; 34:805-812.
38. Tateishi N, Mori T, Kagamiishi Y, Satoh S, Katsube N, Morikawa E, et al. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(−)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab 2002; 22:723-734.
39. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60:540-551.
40. Businaro R, Leone S, Fabrizi C, Sorci G, Donato R, Lauro G, et al. S100B protects LAN-5 neuroblastoma cells against Aβ amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Aβ amyloid neurotoxicity at high doses. J Neurosci Res 2006; 83:897-906.